Icon (ICLR) Expected to Post Quarterly Earnings on Tuesday

Icon (NASDAQ:ICLR) is expected to be releasing its Q3 2026 results after the market closes on Tuesday, October 27th. Analysts expect Icon to post earnings of $2.63 per share and revenue of $2.01 billion for the quarter. Parties can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 8:00 AM ET.

Icon (NASDAQ:ICLR) last announced its earnings results on Thursday, July 30th. The medical research company reported $2.56 EPS for the quarter, beating analysts’ consensus estimates of $2.55 by $0.01. The company had revenue of $2.06 billion during the quarter, compared to analysts’ expectations of $2 billion. Icon had a return on equity of 8.02% and a net margin of 3.99%. Icon’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same period last year, the business posted $3.26 EPS. On average, analysts expect Icon to post $9.56 EPS for the current fiscal year and $10.61 EPS for the next fiscal year.

Icon Stock Performance

NASDAQ ICLR opened at $168.14 on Tuesday. The company has a market cap of $12.87 billion, a P/E ratio of 39.47, a P/E/G ratio of 10.99 and a beta of 1.24. The company has a debt-to-equity ratio of 0.23, a current ratio of 0.95 and a quick ratio of 0.95. The stock has a 50-day moving average of $167.44 and a two-hundred day moving average of $149.92. Icon has a 1-year low of $66.57 and a 1-year high of $203.91.

Insider Transactions at Icon

In other Icon news, CFO Bernard Clerkin sold 2,267 shares of the company’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $164.29, for a total transaction of $372,445.43. Following the sale, the chief financial officer owned 5,881 shares in the company, valued at $966,189.49. This represents a 27.82% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Ciaran Murray sold 2,677 shares of the company’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $164.29, for a total value of $439,804.33. Following the sale, the director owned 20,452 shares in the company, valued at approximately $3,360,059.08. This trade represents a 11.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 22,796 shares of company stock valued at $3,887,139 in the last 90 days. Insiders own 44.00% of the company’s stock.

Wall Street Analysts Forecast Growth

ICLR has been the topic of several research reports. TD Cowen increased their price target on shares of Icon from $164.00 to $197.00 and gave the stock a “buy” rating in a research report on Thursday, June 25th. William Blair raised shares of Icon to a “strong-buy” rating in a research note on Thursday, July 30th. Zacks Research upgraded shares of Icon from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 28th. Royal Bank Of Canada raised shares of Icon from a “sector perform” rating to an “outperform” rating and upped their target price for the stock from $126.00 to $185.00 in a research note on Thursday, June 25th. Finally, BMO Capital Markets upped their target price on shares of Icon from $160.00 to $187.00 and gave the stock an “outperform” rating in a research note on Thursday, June 25th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Icon has a consensus rating of “Hold” and a consensus target price of $174.73.

About Icon

ICON plc is a global contract research organization that provides outsourced development services to pharmaceutical, biotechnology and medical device companies. The company supports clinical research programs from early development through late-stage trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, medical and regulatory consulting, biostatistics, data management, pharmacovigilance, laboratory services and real-world evidence solutions.